TG Therapeutics, Inc. $TGTX Stock Bought by Profund Advisors LLC

Profund Advisors LLC grew its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 26.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 46,230 shares of the biopharmaceutical company’s stock after purchasing an additional 9,717 shares during the period. Profund Advisors LLC’s holdings in TG Therapeutics were worth $2,579,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of TGTX. BlackRock Inc. acquired a new position in shares of TG Therapeutics during the second quarter worth about $1,211,429,000. Bank of America Corp DE lifted its position in shares of TG Therapeutics by 71.7% in the first quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company’s stock valued at $48,544,000 after buying an additional 610,195 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in TG Therapeutics by 129.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock valued at $36,029,000 after purchasing an additional 612,068 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of TG Therapeutics during the 2nd quarter worth about $49,472,000. Finally, Wellington Management Group LLP grew its position in shares of TG Therapeutics by 697.6% in the second quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company’s stock valued at $26,276,000 after purchasing an additional 418,300 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Price Performance

TGTX stock opened at $61.18 on Monday. TG Therapeutics, Inc. has a 52-week low of $26.76 and a 52-week high of $61.76. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The business has a 50-day simple moving average of $55.33 and a two-hundred day simple moving average of $43.75. The company has a market capitalization of $9.36 billion, a P/E ratio of 22.33, a price-to-earnings-growth ratio of 2.58 and a beta of 1.80.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The company had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. During the same quarter last year, the company posted $0.17 EPS. The company’s quarterly revenue was up 70.2% compared to the same quarter last year. Research analysts expect that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Analyst Ratings Changes

TGTX has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Bank of America boosted their price objective on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. B. Riley Financial increased their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Finally, HC Wainwright restated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research report on Tuesday, September 1st. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

Insider Activity

In other news, Director Laurence Charney sold 5,000 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the sale, the director owned 168,640 shares in the company, valued at $9,268,454.40. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.87% of the stock is currently owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.